检索结果-南通市图书馆

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

四川生理科学杂志 2021年第10期43卷 1756-1756页

作者： kevin kalinsky From the Winship Cancer Institute at Emory University Atlanta (K.K.) Southwest Oncology Group Statistics and Data Management Center (W.E.B. D.L.L. J.M.) and the University of Washington School of Medicine–Seattle Cancer Care Alliance (J.R.G.) — both in Seattle the University of Texas M.D. Anderson Cancer Center Houston (F.M.-B. D.T. G.N.H.) Loyola University Chicago Maywood IL (K.S.A.) the University of Michigan Ann Arbor (D.F.H. A.F.S.) Dana–Farber Cancer Institute Boston (N.U.L.) Mayo Clinic Jacksonville FL (E.A.P.) Fox Chase Cancer Center Philadelphia (L.J.G.) and the University of Pittsburgh Pittsburgh (P.R.) — both in Pennsylvania BC Cancer–Vancouver Cancer Centre Vancouver (S.K.L.C.) and Juravinski Cancer Centre at Hamilton Health Sciences Hamilton ON (S.D.-T.) — both in Canada UGCI Medical Oncology Hospital Virgen de la Victoria Instituto de Investigación Biomédica de Málaga Malaga (E.A.) Instituto de Investigación Sanitaria Gregorio Marañón Centro de Investigación Biomédica en Red Cáncer–Instituto de Salud Carlos III Universidad Complutense Madrid (M.M.) Hospital Universitario Virgen del Rocío Seville (M.R.-B.) Institut Català d’Oncologia Barcelona (M.G.-G.) Hospital Clínico Universitario de Valencia Biomedical Research Institute Investigación del Hospital Clínico de la Comunidad Valenciana Valencia (B.B.) and Centro Oncológico de Galicia A Coruña (M.R.-V.) — all in Spain Institut Gustave Roussy (S.D.) and Institut Curie (J.-Y.P.) Paris Institut Curie–Centre Réné Huguenin Saint-Cloud (E.G.C.B.) and Centre Antoine Lacassagne Nice (J.-M.F.) — all in France Mater Misericordiae University Hospital Dublin (C.M.K.) Instituto Nacional de Cancerología de México Mexico City (C.H.A.-S.) the National Cancer Center Korea Goyang-si (E.-S.L.) and Asa Medical Center University of Ulsan College of Medicine Seoul (K.-H.J.) — both in South Korea Exact Sciences Redwood City CA (S.S.) the University of Kansas Medical Center Kansas City (P.S.) and Yale University New Haven CT

Background:The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor-positive,human epidermal growth factor receptor 2(HER2)-negative,axillary lymphnode-negative breast *** women with positive lymph-node disease,the role of the recurrence score with respect to predicting a benefit of adjuvant chemotherapy is ***:In a prospective trial,we randomly assigned women with hormone-receptor-positive,HER2-negative breast cancer,one to three positive axillary lymph nodes,and a recurrence score of 25 or lower(scores range from 0 to 100,with higher scores indicating a worse prognosis)to endocrine therapy only or to chemotherapy plus endocrine(chemoendocrine)*** primary objective was to determine the effect of chemotherapy on invasive disease-free survival and whether the effect was influenced by the recurrence *** end points included distant relapse-free survival.

关键词： chemotherapy Breast Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：